Marzia Palma

Publications
CV
Public outreach and news

Articles

Article: CANCERS. 2024;16(22):3821
A Small Molecule Antagonist of CX3CR1 (KAND567) Inhibited the Tumor Growth-Promoting Effect of Monocytes in Chronic Lymphocytic Leukemia (CLL)
Zhong W; Kokhaei P; Mulder TA; Ghaderi A; Moshfegh A; Lundin J; Palma M; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Journal article: BLOOD. 2024;144(Supplement 1):6756
Cellular and Molecular Effects of Suspending Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia in Sustained Partial Remission
Palma M; Andersson ML; Mulder TA; Heimersson K; Berglöf A; Peña Perez L; Del Peso Santos T; Alvarado Valero Y; Zain-Luqman R; Månsson R; Rosenquist R; Smith ECI; Österborg A; Lundin J
Journal article: BLOOD NEOPLASIA. 2024;1(2):100006
Frequent response monitoring in chronic lymphocytic leukemia clinical trials: what is the value?
Mattsson A; Lundin J; Mulder TA; Sylvan SE; Palma M; Hansson L; Österborg A
Journal article: BLOOD. 2023;142:5716
A CX3CR1 (fractalkine receptor) Small Molecular Antagonist (KAND567) Suppressed the Growth Promoting Effect of Monocytes on Chronic Lymphocytic Leukemia Cells
Hojjat-Farsangi M; Zhong W; Mulder T; Svensson A; Lundin J; Palma M; Schultz J; Olin T; Wahlin B; Osterborg A; Kokhaei P; Mellstedt H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;111(5):748-756
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib-A retrospective analysis on consecutive patients from a well-defined region
Andersson ML; Johansson H; Osterborg A; Mansson-Broberg A; Hansson L; Palma M
Journal article: HEMASPHERE. 2023;7(Suppl):e18051e0
P609: EFFECT OF LONG‐TERM ZANUBRUTINIB TREATMENT ON T‐CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A STUDY CONDUCTED IN PARALLEL WITH THE BGB‐3111‐304 AND 305 TRIALS.
Andersson M; Mulder TA; Heimersson K; Sönnert‐Husa S; Giertz A; Hansson L; Karlsson C; Lundin J; Österborg A; Palma M
Journal article: HEMASPHERE. 2023;7(Suppl):e28011bd
PB1924: INCIDENCE OF CARDIOVASCULAR AND BLEEDING EVENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL) TREATED WITH IBRUTINIB – A RETROSPECTIVE ANALYSIS ON CONSECUTIVE PATIENTS FROM A WELL‐DEFINED REGION.
Andersson M; Johansson H; Österborg A; Månsson‐Broberg A; Hansson L; Palma M
Article: JOURNAL OF HEMATOLOGY. 2023;12(4):170-175
Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia
Andersson M; Wu J; Wullimann D; Gao Y; Aberg M; Muschiol S; Healy K; Naud S; Bogdanovic G; Palma M; Mellstedt H; Chen P; Ljunggren H-G; Hansson L; Chen MS; Buggert M; Ingelman-Sundberg HM; Osterborg A
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):677
TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME OF PATIENTS WITH HODGKIN LYMPHOMA EXPERIENCING VERY LATE RELAPSES AFTER CHEMOTHERAPY ± RADIOTHERAPY
Vassilakopoulos TP; Liaskas A; Rizzuto G; Symeonidis A; Palma M; Angelopoulou MK; Giatra C; Spanoudakis E; Oikonomopoulos P; Kondopidou FN; Dimou M; Musseti A; Xagoraris I; Siakantaris M; Panitsas F; Asimakopoulos J; Arapaki M; Chatzidimitriou C; Belia M; Sachanas S; Korkolopoulou P; Cabras A; Variami E; Panayotidis P; Bakiri M; Karmiris T; Rassidakis G; Corradini P; Pangalis GA; Viviani S
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):369-370
Secondary cancer is the leading cause of death 15 years or more after diagnosis of early‐stage Hodgkin lymphoma
Lagerlöf I; Fohlin H; Enblad G; Glimelius B; Goldkuhl C; Palma M; Glimelius I; Molin D
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:318
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
Xagoraris I; Mulder T; Stathopoulou K; Xyderou P; Andersson M; Palma M; Rassidakis G
Article: HEMASPHERE. 2022;6(11):e794
Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment
Mulder TAA; Andersson MLL; Pena-Perez L; Heimersson K; Xagoraris I; Wahlin BE; Mansson R; Hansson L; Rassidakis G; Palma M
Journal article: HEMASPHERE. 2022;6(Suppl):53
P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
Vassilakopoulos TP; Liaskas A; Rizzuto G; Symeonidis A; Palma M; Angelopoulou MK; Giatra C; Kondopidou F; Dimou M; Musseti A; Xagoraris I; Siakantaris M; Verigou E; Panitsas F; Asimakopoulos J; Arapaki M; Chatzidimitriou C; Belia M; Sachanas S; Korkolopoulou P; Cabras A; Variamis E; Panayiotidis P; Bakiri M; Karmiris T; Rassidakis GZ; Corradini P; Pangalis G; Viviani S
Journal article: HEMASPHERE. 2022;6(Suppl):24
P053: The cGAS‐STING anti‐tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)
Xagoraris I; Stathopoulou K; Xyderou P; Palma M; Drakos E; Vassilakopoulos TP; Rassidakis GZ
Journal article: HEMASPHERE. 2022;6(Suppl ):42
P091: Early analysis of the PRO-Hodgkin study: Clinical investigation of pencil beam scanning proton treatment in Hodgkin lymphoma patients
Goldkuhl C; Dasu A; Bäck A; Enblad G; Glimelius I; Hall A; Hansson L; Jerlström. U; Johansson A-S; Kahlmeter-Brandell J; Linderoth J; Palma M; Rylander H; Enmark M; Molin D
Journal article: HEMASPHERE. 2022;6(Suppl ):15-16
P032: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.
Mulder TA; Andersson ML; Peña-Pérez L; Heimersson K; Xagoraris I; Wahlin BE; Månsson R; Hansson L; Rassidakis GZ; Palma M
Journal article: HEMASPHERE. 2022;6(Suppl ):1168-1169
P1283: CIRCULATING IMMUNE CELLS IN CLASSICAL HODGKIN LYMPHOMA IN RELATION TO TUMOR BURDEN AND TREATMENT
Mulder TA; Andersson ML; Heimersson K; Xagoraris I; Wahlin BE; Rassidakis G; Hansson L; Palma M
Article: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(13):1487-1496
Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy
Lagerlof I; Fohlin H; Enblad G; Glimelius B; Goldkuhl C; Palma M; Akesson L; Glimelius I; Molin D
Article: LEUKEMIA. 2022;36(2):476-481
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients
Blixt L; Bogdanovic G; Buggert M; Gao Y; Hober S; Healy K; Johansson H; Kjellander C; Mravinacova S; Muschiol S; Nilsson P; Palma M; Pin E; Smith CIE; Stromberg O; Chen MS; Zain R; Hansson L; Osterborg A
Article: EJHAEM. 2021;2(3):525-529
Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia
Lundin J; Mulder TA; Kattstrom M; Wasterlid T; Uddevik A; Mellstedt H; Heimersson K; Hansson L; Palma M; Osterborg A
Article: EJHAEM. 2021;2(3):498-502
A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1⁺ CLL cells
Ghaderi A; Okhovat M-A; Wikanthi LSS; Svensson A; Palma M; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: EJHAEM. 2021;2(3):400-412
Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years
Wahlin BE; Overgaard N; Peterson S; Digkas E; Glimelius I; Lagerlof I; Johansson A-S; Palma M; Hansson L; Linderoth J; Goldkuhl C; Molin D
Article: HEMASPHERE. 2021;5(5):e564
Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia
Mulder TA; Pena-Perez L; Berglof A; Meinke S; Estupinan HY; Heimersson K; Zain R; Mansson R; Smith CIE; Palma M
Journal article: HEMASPHERE. 2021;5(5)
Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia
Mulder TA; Pena-Perez L; Berglof A; Meinke S; Estupinan HY; Heimersson K; Zain R; Mansson R; Smith CIE; Palma M
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;188(5):685-691
No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy
Lagerlof I; Holte H; Glimelius I; Bjorkholm M; Enblad G; Erlanson M; Fluge O; Fohlin H; Fossa A; Goldkuhl C; Gustavsson A; Johansson A-S; Linderoth J; Nome O; Palma M; Akesson L; Ostenstad B; Raud C; Glimelius B; Molin D
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;183(2):212-224
Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes
Palma M; Krstic A; Perez LP; Bergloef A; Meinke S; Wang Q; Blomberg KEM; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; De Paepe A; Hoeglund P; Kimby E; OEsterborg A; Mansson R; Smith CIE
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2018;101(1):68-77
Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients
Palma M; Hansson L; Mulder TA; Adamson L; Nasman-Glaser B; Eriksson I; Heimersson K; Ryblom H; Mozaffari F; Svensson A; Gentilcore G; Osterborg A; Mellstedt H
Article: CLINICAL CANCER RESEARCH. 2018;24(8):1834-1844
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
Bjorklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikstrom K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellstrom-Lindberg E; Ljunggren H-G; Malmberg K-J
Article: PLOS ONE. 2018;13(2):e0192839
Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells
Kokhaei P; Hojjat-Farsangi M; Mozaffari F; Moshfegh A; Pak F; Rashidy-Pour A; Palma M; Hansson L; Osterborg A; Mellstedt H
Article: HAEMATOLOGICA. 2017;102(3):562-572
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
Palma M; Gentilcore G; Heimersson K; Mozaffari F; Nasman-Glaser B; Young E; Rosenquist R; Hansson L; Osterborg A; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2017;66(1):91-102
Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
Winqvist M; Mozaffari F; Palma M; Sylvan SE; Hansson L; Mellstedt H; Osterborg A; Lundin J
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2015;45(6):1783-1793
Dendritic cell regulation of NK-cell responses involves lymphotoxin-, IL-12, and TGF-
Sarhan D; Palma M; Mao Y; Adamson L; Kiessling R; Mellstedt H; Osterborg A; Lundqvist A
Journal article: BLOOD. 2014;124(21):1120
Early and Transient Microchimerism Associated with Complete Remission after Adoptively Transferred Haploidentical NK Cells Against High Risk Myelodysplastic Syndrome and Refractory Acute Myeloid Leukemia
Bjorklund AT; Carlsten M; Schaffer M; Liu L; Cooley SA; Miller JS; Watz E; Palma M; Hansson L; Wahlin BE; Mollgard L; Hagglund H; Blomberg P; Ljungman PT; Hellstrom-Lindberg E; Ljunggren H-G; Malmberg K-J
Article: ANNALS OF HEMATOLOGY. 2014;93(10):1725-1733
Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients
Sylvan SE; Lundin J; Ipek M; Palma M; Karlsson C; Hansson L
Journal article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2014;2(Suppl 2):p18
P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients
Sylvan SE; Lundin J; Ipek M; Palma M; Karlsson C; Hansson L
Article: EXPERIMENTAL HEMATOLOGY. 2013;41(7):615-626
Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia
Palma M; Parker A; Hojjat-Farsangi M; Forster J; Kokhaei P; Hansson L; Osterborg A; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2013;62(1):51-63
T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile
Kiaii S; Kokhaei P; Mozaffari F; Rossmann E; Pak F; Moshfegh A; Palma M; Hansson L; Mashayekhi K; Hojjat-Farsangi M; Osterborg A; Choudhury A; Mellstedt H
Article: PLOS ONE. 2013;8(10):e78339
The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.
Hojjat-Farsangi M; Khan AS; Daneshmanesh AH; Moshfegh A; Sandin A; Mansouri L; Palma M; Lundin J; Österborg A; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2012;61(6):865-879
Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria
Palma M; Hansson L; Choudhury A; Nasman-Glaser B; Eriksson I; Adamson L; Rossmann E; Widen K; Horvath R; Kokhaei P; Vertuani S; Mellstedt H; Osterborg A
Journal article: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2011;11:s145
1.7 Telomere Length and Expression of Human Telomerase Reverse Transcriptase Splice Variants in Chronic Lymphocytic Leukemia
Palma M; Parker A; Forster J; Kokhaei P; Hansson L; Hojjat-Farsangi M; Österborg A; Mellstedt H
Journal article: BLOOD. 2010;116(21):2413
Expression of Human Telomerase Reverse Transcriptase (hTERT) Splice Variants In Chronic Lymphocytic Leukemia (CLL)
Palma M; Kokhaei P; Hansson L; Hojat-Farsangi M; Choudhury AR; Osterborg A; Mellstedt H
Article: MINERVA CHIRURGICA. 2009;64(6):643-653
Cancer vaccines for non-small-cell lung cancer
Palma M; Choudhury A; Mellstedt H
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2009;69(6):529-536
Generation of a Dendritic Cell-based Vaccine in Chronic Lymphocytic Leukaemia Using CliniMACS Platform for Large-scale Production
Adamson L; Palma M; Choudhury A; Eriksson I; Nasman-Glaser B; Hansson M; Hansson L; Kokhaei P; Osterborg A; Mellstedt H
Journal article: BLOOD. 2008;112(11):2071
T Cells from Patients with Chronic Lymphocytic Leukaemia Prevent Apoptosis of Autologous CLL Cells in a Dose- and Cell:Cell-Contact Dependent Fashion; Rationale for New Therapeutic Possibilities.
Rossmann E; Kokhaei P; Mozaffari F; Palma M; Osterborg A; Mellstedt H; Choudhury AR
Article: CLINICAL LUNG CANCER. 2008;9:S37-S44
The future of cancer vaccines for non-small-cell lung cancer: Ongoing trials
Choudhury A; Palma M; Mellstedt H
Journal article: BLOOD. 2007;110(11):2061
Immunological Responses in CLL Patients Vaccinated with Autologous Dendritic Cells Loaded with Apoptotic Bodies (Apo-DC).
Choudhury A; Palma M; Hansson L; Widen K; Eriksson I; Nasman-Glaser B; Adamson L; Osterborg A; Mellstedt H
Article: EXPERIMENTAL HEMATOLOGY. 2007;35(2):297-304
Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells
Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
Article: CYTOTHERAPY. 2006;8(4):318-326
Generation of DC-based vaccine for therapy of B-CLL patients.: Comparison of two methods for enriching monocytic precursors
Kokhaei P; Adamson L; Palma M; Osterborg A; Pisa P; Choudhury A; Mellstedt H
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(16_suppl):2577
Telomerase - a tumor antigen in chronic lymphocytic leukemia (CLL) induces spontaneously autologous leukemia specific cytotoxic T lymphocytes
Kokhaei P; Palma M; Hansson L; Ã-sterborg A; Choudhury A; Mellstedt H
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2004;279(29):30830-30835
Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage.
Ianari A; Gallo R; Palma M; Alesse E; Gulino A
Article: ANTICANCER RESEARCH. 2003;23(2C):1917-1922
Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer.
Mancuso A; Giuliani R; Accettura C; Palma M; D'Auria G; Cecere F; Paoluzzi L; Bezzi M; Massidda B; Cortesi E
Article: TUMORI. 2002;88(6):527-529
Atrial fibrillation during adjuvant chemotherapy with docetaxel: a case report.
Palma M; Mancuso A; Grifalchi F; Lugini A; Pizzardi N; Cortesi E
Article: TUMORI. 2000;86(5):424-427
Fulminant hepatic failure caused by diffuse intrasinusoidal metastatic liver disease: a case report.
Martelli O; Coppola L; De Quarto AL; Palma M; Sarmiento R; Foggi CM
Show more

All other publications

Letter: ACTA ONCOLOGICA. 2023;62(6):560-564
The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results
Smedby KE; Waesterlid T; Tham E; Haider Z; Joelsson J; Thorvaldsdottir B; Krstic A; Wahlin BE; Foroughi-Asl H; Karlsson C; Eloranta S; Saft L; Palma M; Kwiecinska A; Hansson L; Osterborg A; Wirta V; Rassidakis G; Sander B; Sonnevi K; Rosenquist R
Meeting abstract: BLOOD. 2022;140:3579-3580
Modulation of the CGAS-Sting Anti-Tumor Immune Response Pathway in an NF-KB-Dependent or -Independent Manner As a Potential Therapeutic Target in Classical Hodgkin Lymphoma (cHL)
Xagoraris I; Stathopoulou K; Xyderou P; Palma M; Drakos E; Vassilakopoulos TP; Rassidakis GZ
Review: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2022;95(4):e13153
Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukaemia?
Smith CIE; Zain R; osterborg A; Palma M; Buggert M; Bergman P; Bryceson Y
Review: FRONTIERS IN IMMUNOLOGY. 2021;12:686768
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects
Palma M; Mulder TA; Osterborg A
Conference publication: LEUKEMIA AND LYMPHOMA. 2020;61:81-84
Effect of long-term ibrutinib treatment on T-cell number and profile in relapsed or refractory chronic lymphocytic leukemia patients: correlation with clinical response and tumor burden up to 4-years follow-up
Palma M; Heimersson K; Mulder T; Mellstedt H; Osterborg A
Conference publication: BLOOD. 2019;134:5445
Expression of the Fractalkine Receptor (CX3CR1) Is Significantly Increased in Immune Cells of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma patients with Active Disease
Palma M; Mulder TA; Heimersson K; Rathje L-S; Olin T; Schultz J; Mellstedt H; Osterborg A
Review: CANCERS. 2019;11(7):E915-915
Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application
Mulder TA; Wahlin BE; Osterborg A; Palma M
Meeting abstract: BLOOD. 2018;132:4421
Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatement in Relapsed or Refactory Chronic Lymphocytic Leukemia Patients
Palma M; Heimersson K; Mulder TA; Nasman-Glaser B; Osterborg A; Mellstedt H
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2018;182(4):590-594
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study
Winqvist M; Palma M; Heimersson K; Mellstedt H; OEsterborg A; Lundin J
Conference publication: BLOOD. 2017;130
Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML
Bjorklund AT; Carlsten M; Sohlberg E; Clancy T; Liu L; Karimi M; Cooley S; Miller JS; Watz E; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellstrom-Lindberg E; Ljunggren H-G; Malmberg K-J
Conference publication: LEUKEMIA AND LYMPHOMA. 2017;58:38-39
Vaccination with dendritic cells loaded with autologous leukemic cells in combination with low-dose lenalidomide in chronic lymphocytic leukemia (CLL) patients: an early clinical trial
Heimersson K; Mozaffari F; Mulder T; Palma M; Hansson L; Adamson L; Nasman-Glaser B; Svensson A; Gentilcore G; Osterborg A; Mellstedt H
Meeting abstract: BLOOD. 2016;128(22):3235
Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients
Palma M; Krstic A; Berglof A; Wang Q; Blomberg E; Meinke S; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; Kimby E; Hoglund P; Mansson R; Osterborg A; Smith E
Conference publication: HAEMATOLOGICA. 2016;101:22
HODGKIN LYMPHOMA IN SWEDEN SINCE 2000: BETTER SURVIVAL ONLY IN ELDERLY WOMEN - A SWEDISH LYMPHOMA REGISTRY STUDY
Wahlin BE; Overgaard N; Peterson S; Digkas E; Glimelius I; Lagerlof I; Johansson A-S; Palma M; Hansson L; Linderoth J; Goldkuhl C; Molin D
Conference publication: EUROPEAN JOURNAL OF CANCER. 2016;55:S7
Expression of immune checkpoint molecules and activation markers in T cells from chronic lymphocytic leukemia (CL) patients
Palma M; Gentilcore G; Mozaffari F; Heimersson K; Nasman-Glaser B; Hansson L; Osterborg A; Mellstedt H
Conference publication: HAEMATOLOGICA. 2016;101:9
PHENOTYPIC CHARACTERIZATION OF CIRCULATING LYMPHOCYTES IN HODGKIN'S LYMPHOMA WITH FOCUS ON T CELLS
Palma M; Heimersson K; Nasman-Glaser B; Hansson L
Conference publication: BLOOD. 2015;126(23):4164
In Vivo Effects of Lenalidomide on T Cell Proliferation and Immune Checkpoint Molecules in Patients with Advanced Stage CLL: Results from a Phase II Study
Winqvist M; Mozaffari F; Palma M; Sylvan SE; Mellstedt H; Osterborg A; Lundin J
Conference publication: BLOOD. 2015;126(23):4132
T Cells from Chronic Lymphocytic Leukemia (CLL) Patients Display Dysregulated Expression of Immune Checkpoint Molecules and Activation Markers Mainly Restricted to CD4⁺ Cells and Correlated with Disease Activity
Palma M; Gentilcore G; Mozaffari F; Heimersson K; Nasman-Glaser B; Hansson L; Osterborg A; Mellstedt H
Review: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2015;82(3):208-217
Targets for Ibrutinib Beyond B Cell Malignancies
Berglof A; Hamasy A; Meinke S; Palma M; Krstic A; Mansson R; Kimby E; Osterborg A; Smith CIE
Meeting abstract: LEUKEMIA RESEARCH. 2015;39:S25-S26
ADOPTIVELY TRANSFERRED HAPLOIDENTICAL NK CELLS AGAINST REFRACTORY MDS, HIGH-RISK MDS AND REFRACTORY AML AS A BRIDGE TO TRANSPLANTATION. COMPLETE REMISSION ASSOCIATED WITH DETECTABLE NK CELLS
Bjorklund AT; Carlsten M; Liu L; Schaffer M; Watz E; Palma M; Hansson L; Mollgard L; Cooley SA; Miller JS; Ljungman PT; Hellstrom-Lindberg E; Ljunggren HG; Malmberg KJ
Conference publication: BLOOD. 2014;124(21):4685
Vaccination with Dendritic Cells Loaded with Autologous Leukemic Cells in Combination with Low-Dose Lenalidomide Induced Immune Responses in Chronic Lymphocytic Leukemia (CLL) Patients
Hansson L; Palma M; Adamson L; Ryblom H; Nasman-Glaser B; Eriksson I; Heimersson K; Gentilcore G; Mellstedt H; Osterborg A
Conference publication: BLOOD. 2014;124(21):4140
Regulation of Natural Killer Cell Responses By Dendritic Cells Via Lymphotoxin-Alpha, Interleukin-12, and Tumor Growth Factor-Beta
Sarhan D; Palma M; Mao Y; Adamson L; Kiessling R; Mellstedt H; Osterborg A; Lundqvist A
Conference publication: BONE MARROW TRANSPLANTATION. 2014;49:S134-S135
INTERIM REPORT OF A CLINICAL STUDY WITH HAPLOIDENTICAL NK-CELLS AGAINST HIGH RISK MDS AND AML
Bjorklund AT; Carlsten M; Liu L; Er MS; Cooley S; Miller JS; Watz E; Wahlin B; Palma M; Hansson L; Ljungman P; Hellstrom-Lindberg E; Ljunggren H-G; Malmberg K-J
Thesis / dissertation: 2010
Immunological and molecular studies for the development of vaccine therapy for chronic lymphocytic leukemia
Palma, Marzia
Conference publication: HAEMATOLOGICA. 2010;95:476
VACCINATION WITH DENDRITIC CELLS LOADED WITH APOPTOTIC BODIES (APO-DC) OF AUTOLOGOUS LEUKEMIC CELLS INDUCES IMMUNOLOGIC RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
Hansson L; Palma M; Adamson L; Eriksson I; Nasman-Glaser B; Kokhaei P; Widen K; Choudhury A; Osterborg A; Mellstedt H
Conference publication: BLOOD. 2010;116(21):1001
Expression of Human Telomerase Reverse Transcriptase (hTERT) Splice Variants In Chronic Lymphocytic Leukemia (CLL)
Palma M; Kokhaei P; Hansson L; Hojat-Farsangi M; Choudhury AR; Osterborg A; Mellstedt H
Published conference paper: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2008;57(11):1705-1710
Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia
Palma M; Adamson L; Hansson L; Kokhaei P; Rezvany R; Mellstedt H; Oesterborg A; Choudhury A
Conference publication: ANNALS OF ONCOLOGY. 2008;19:164
VACCINATION OF CLL PATIENTS WITH AUTOLOGOUS DENDRITIC CELLS LOADED WITH APOPTOTIC BODIES (APO-DC): A PHASE I-II CLINICAL TRIAL
Palma M; Hansson L; Adamson L; Eriksson I; Nasman-Glaser B; Widen K; Choudhury AR; Osterborg A; Mellstedt H
Conference publication: BLOOD. 2008;112(11):721
T Cells from Patients with Chronic Lymphocytic Leukaemia Prevent Apoptosis of Autologous CLL Cells in a Dose- and Cell:Cell-Contact Dependent Fashion; Rationale for New Therapeutic Possibilities
Rossmann E; Kokhaei P; Mozaffari F; Palma M; Osterborg A; Mellstedt H; Choudhury AR
Conference publication: ANNALS OF ONCOLOGY. 2008;19:234-235
T CELLS FROM CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS SUPPORT TUMOR CELL SURVIVAL IN VITRO
Kokhaei P; Mozaffari F; Palma M; Rosmann E; Osterborg A; Mellstedt H
Conference publication: BLOOD. 2007;110(11):614A
Immunological responses in CLL patients vaccinated with autologous dendritic cells loaded with apoptotic bodies (Apo-DC)
Choudhury A; Palma M; Hansson L; Widen K; Eriksson I; Nasman-Glaser B; Adamson L; Osterborg A; Mellstedt H
Published conference paper: ANNALS OF ONCOLOGY. 2006;17:X144-X154
The biology and treatment of chronic lymphocytic leukemia
Palma M; Kokhaei P; Lundin J; Choudhury A; Mellstedt H; Osterborg A
Conference publication: ANNALS OF ONCOLOGY. 2006;17:207
Vaccination of B-CLL patients with autologous dendritic cells loaded with leukemia-derived apoptotic bodies
Choudhury A; Hansson L; Palma M; Kokhaei P; Adamson L; Osterborg A; Mellstedt H
Conference publication: ANNALS OF ONCOLOGY. 2006;17:60-61
HTERT (human telomerase reverse transcriptase) Σ-insert splice variant (INS1) expression in B-chronic lymphocytic leukemia (B-CLL)
Palma M; Kokhaei P; Kiaii S; Nasman-Glaser B; Hansson L; Osterborg A; Choudhury A; Mellstedt H
Review: ADVANCES IN CANCER RESEARCH. 2006;95:147-202
Clinical results of vaccine therapy for cancer: Learning from history for improving the future
Choudhury A; Mosolits S; Kokhaei P; Hansson L; Palma M; Mellstedt H
Review: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. 2006;57(1):1-23
BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.
Palma M; Ristori E; Ricevuto E; Giannini G; Gulino A
Conference publication: EXPERIMENTAL HEMATOLOGY. 2005;33(7):97
A telomerase-derived peptide antigen generates antileukemic T cells from B-CLL patients in vitro
Choudhury A; Palma M; Kokhaei P; Hanson L; Osterborg A; Mellstedt H
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(16):185S
Telomerase - a tumor antigen in chronic lymphocytic leukemia (CLL) induces spontaneously autologous leukemia specific cytotoxic T lymphocytes.
Kokhaei P; Palma M; Hansson L; A-sterborg A; Choudhury A; Mellstedt H
Published conference paper: ANNALS OF ONCOLOGY. 2005;16:ii113-ii123
Biology and treatment of chronic lymphocytic leukemia
Kokhaei P; Palma A; Mellstedt H; Choudhury A
Show more

Employments

Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2023-2026

Degrees and Education

Docent, Oncology, Karolinska Institutet, 2023
Degree Of Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2010

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI